ClinicalTrials.gg
CompletedNCT00064402Updated Feb 22, 2012

Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

A Phase 3 interventional study of arformoterol tartrate inhalation solution and arformoterol tartrate inhalation solution in Chronic Obstructive Pulmonary Disease, Chronic Bronchitis and Emphysema, sponsored by Sumitomo Pharma America, Inc.. Completed at 65 sites in United States. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2012-02-22.

Primary conditionBronchitis, ChronicRegistry: Pulmonary Disease, Chronic ObstructiveReclassifiedWhy we changed it
Registry
Pulmonary Disease, Chronic Obstructive — the first condition term the registry derived for this study.
ClinicalTrials.gg
Bronchitis, Chronic
Why
  1. The study's listed conditions name Bronchitis, Chronic, a narrower term within Pulmonary Disease, Chronic Obstructive.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
741
Allocation
Randomized
Ages
35 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 100 studies in Bronchitis, Chronic with a site in United States — 7 open to participants now, 12 under way, none of them phase 3. Bronchitis, Chronic · United States.

Enrollment
11th of 82
741 · median 126
Started
2002
with 4 others
Phase 3
19 of 100
none open now
Registered
3rd of 100
by date
Lead sponsor
7 of 100
Sumitomo Pharma America, Inc.

Among the 100 studies in Bronchitis, Chronic with a site in United States, this one is the 11th largest by enrollment of the 82 interventional ones that give a count, is one of 5 that started in 2002, is one of 19 in phase 3, and was the 3rd registered.

Bronchitis, Chronic

209 studies on the registry are indexed under Bronchitis, Chronic; 14 are open to participants now.

Browse Bronchitis, Chronic studies →

Open to participants now

7 of the 100 studies in Bronchitis, Chronic with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Bronchitis, Chronic studies recruiting now, 5 (50%) set no upper age limit and 2 (20%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 35 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies in Bronchitis, Chronic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the bronchodilator effect and safety of multiple daily doses of arformoterol administered for 12 weeks as maintenance treatment in patients with COPD

Read the detailed description

This was a double-blind, double-dummy, randomized, placebo- and active-controlled, multicenter, parallel-group study of adult subjects with COPD. The study was double blinded through the use of both unit dose vial (UDV) and metered-dose inhaler (MDI) placebos, as appropriate. The primary efficacy analysis utilized the placebo control. Secondary analyses of the primary efficacy endpoint utilized the active control, and included comparisons between the placebo and active control. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
  • Chronic Bronchitis
  • Emphysema

Browse trials for

04

In context

Bronchitis, Chronic Reclassified

209 studies on the registry are indexed under Bronchitis, Chronic; 14 are open to participants now.

This study's enrollment of 741 is above the median of 101 across 154 interventional studies indexed under Bronchitis, Chronic.

Browse Bronchitis, Chronic studies →

Lead sponsor

Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.

First submitted before Sumitomo Pharma America, Inc. became part of Sumitomo Pharma Co., Ltd..

Compared within Bronchitis, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pulmonary Disease, Chronic Obstructive. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
35 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be willing to comply with study procedures and visit schedule
  • Are at least 35 years of age
  • Female subjects >65 years of age must have a serum pregnancy test conducted at Visit 1 and confirmed negative prior to randomization
  • Subjects of must be using an acceptable method of . Female subjects who are considered not of childbearing potential must be: documented surgically sterile, OR .
  • Have a primary diagnosis of . Diagnosis can be made during the screening process.
  • Have a minimum smoking history of 15 pack-years (pack-years = the number of cigarette packs per day times the number of years).
  • Have a chest x-ray that is consistent with the diagnosis of COPD and taken \<3 months prior to study start
  • Able to complete all study questionnaires and logs reliably

Exclusion criteria

Exclusion Criteria:

  • Female subject who is pregnant or lactating
  • Have participated in an drug study within 30 days prior to study start, or who is currently participating in another investigational drug study
  • Subject whose schedule or travel prevents the completion of all required visits
  • Are scheduled for in-patient hospitalization, including elective surgery during the trial
  • Have life-threatening/unstable respiratory status, including upper or lower respiratory tract infection, within the previous 30 days
  • History of asthma or any chronic respiratory disease other than (chronic bronchitis and/or emphysema)
  • Have cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, or psychiatric disorder that may interfere with successful completion of this protocol
  • Have a history of cancer except non-melanomatous skin cancer
  • Have a history of lung resection of more than one full lobe
  • Requires continuous supplemental oxygen therapy.
  • Has had a change in dose or type of any medications for COPD within 14 days prior to the screening visit
  • Have a known sensitivity to arformoterol, ipratropium, salmeterol or albuterol or any of the contained in any of these formulations
  • Have a history of substance abuse or drug abuse within 12 months, or with a positive urine drug screen
  • Are using any prescription drug for which concomitant beta-agonist administration is (e.g., beta-blockers)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
741 participants (actual)

Study arms

  • Experimental
    1

    Arformoterol 50 mcg QD and placebo MDI

    Drug: arformoterol tartrate inhalation solution

  • Experimental
    2

    Arformoterol 25 mcg BID and Placebo MDI

    Drug: arformoterol tartrate inhalation solution

  • Experimental
    3

    Arformoterol 15 mcg BID and placebo MDI

    Drug: arformoterol tartrate inhalation solution

  • Active comparator
    4

    Salmeterol MDI 42 mcg BID and placebo inhalation solution

    Drug: Salmeterol

  • Placebo comparator
    5

    Placebo MDI and placebo inhalation solution

    Drug: Placebo

Interventions

  • Drugarformoterol tartrate inhalation solution

    arformoterol 50 mcg QD

    Also known as: (R,R)-formoterol

  • Drugarformoterol tartrate inhalation solution

    arformoterol 25 mcg BID

    Also known as: (R,R)-formoterol

  • arformoterol 15 mcg BID

    Also known as: (R,R)-formoterol, Brovana

  • Salmeterol MDI 42 mcg BID

    Also known as: Serevent MDI

  • DrugPlacebo

    Placebo BID

07

What researchers measure

Primary outcomes

  1. percent change in trough FEV1 from study baseline to the end of the dosing interval (12 hours post-second dose for the BID treatment arms and 24 hours postdose for the QD treatment arm) over the double-blind period.

    Time frame: Weeks -2, 0, 3, 6, 9, 12

Secondary outcomes

  1. time-normalized area under the percent change from visit predose curve for FEV1 over 12 hours (nAUC0-12-P)

    Time frame: Weeks -2, 0, 3, 6, 9, 12

  2. Peak percent of predicted FEV1

    Time frame: Weeks -2, 0, 3, 6, 9, 12

  3. time-normalized area under the percent change in FEV1 from study baseline over 12 hours (nAUC0-12-B)

    Time frame: Weeks -2, 0, 3, 6, 9, 12

  4. time-normalized area under the percent change from visit predose curve for FEV1 over 24 hours (nAUC0-24-P)

    Time frame: Weeks -2, 0, 3, 6, 9, 12

  5. time-normalized area under the percent change in FEV1 from study baseline curve over 24 hours (nAUC0-24-B)

    Time frame: Weeks -2, 0, 3, 6, 9, 12

  6. peak percent change in FEV1 from visit predose and study baseline

    Time frame: Weeks -2, 0, 3, 6, 9, 12

  7. time point changes in FEV1; time to onset of response

    Time frame: Weeks -2, 0, 3, 6, 9, 12

  8. time to peak change in FEV1

    Time frame: Weeks -2, 0, 3, 6, 9, 12

  9. at-home and in-clinic peak expiratory flow rate (PEFR)

    Time frame: Weeks -2, 0, 3, 6, 9, 12

  10. relationship between the plasma concentration values and selected pharmacodynamic parameters

    Time frame: Weeks -2, 0, 3, 6, 9, 12, 13

  11. Supplemental ipratropium bromide MDI and racemic albuterol MDI use

    Time frame: Weeks 0-13

  12. COPD exacerbations and COPD symptom ratings

    Time frame: Weeks 0-13

  13. St. George's Hospital Respiratory Questionnaire

    Time frame: Weeks 0, 6, 13

  14. Investigator and Subject Global Evaluations

    Time frame: Weeks -2, 12, 13

  15. Baseline and Transitional Dyspnea Index

    Time frame: Weeks -2, 6, 12

  16. distance walked in six minutes

    Time frame: Weeks -2, 3, 9

08

Study locations

65 sites
  • Pulmonary & Sleep Associates of Jasper, PC
    Jasper, Alabama 35501, United States
  • Pulmonary Associates, PA
    Phoenix, Arizona 85006, United States
  • Arizona Clinical Research Center, Inc.
    Tucson, Arizona 85712, United States
  • Northern California Research Corp.
    Fair Oaks, California 95628, United States
  • SARC Research Center
    Fresno, California 93720, United States
  • California Research Medical Group, Inc.
    Fullerton, California 92835, United States
  • Radiant Research-Irvine
    Irvine, California 92618, United States
  • West Coast Clinical Trials
    Newport Beach, California, United States
  • Center for Clinical Trials, LLC
    Paramount, California 90723, United States
  • Advances in Medicine
    Rancho Mirage, California 92270, United States
  • Institute of Healthcare Assessment, Inc.
    San Diego, California 92120, United States
  • San Jose Clinical Research
    San Jose, California, United States
  • Allergy & Asthma Medical Group of Diablo Valley, Inc.
    Walnut Creek, California 94598, United States
  • Colorado Pulmonary Associates
    Denver, Colorado 80218, United States
  • Northern Colorado Pulmonary Consultants, PC
    Fort Collins, Colorado, United States
  • Physicians Research Center, Inc.
    Hartford, Connecticut 06106, United States
  • Washington Hospital Center
    Washington, District of Columbia, United States
  • Clinical Research of West Florida, Inc.
    Clearwater, Florida 33765, United States
  • University Clinical Research, DeLand
    DeLand, Florida 32720, United States
  • Mt. Sinai Medical Center
    Miami Beach, Florida 33140, United States
  • Clinical Pharmacology Services
    Tampa, Florida 33617, United States
  • Protocare Trial, Inc.
    Austell, Georgia 30106, United States
  • Marietta Pulmonary Medicine
    Marietta, Georgia 30060, United States
  • Office of Bradley Sakran, MD, PC
    O'Fallon, Illinois 62269, United States
  • South Bend Clinic
    South Bend, Indiana 46617, United States
  • Family Allergy & Asthma Research Institute
    Louisville, Kentucky 40215, United States
  • Cumberland Lung and Sleep Specialists
    Somerset, Kentucky, United States
  • Bendel Medical Associates/Research
    Lafayette, Louisiana 70503, United States
  • Best Clinical Trials, LLC
    New Orleans, Louisiana 70115, United States
  • New Orleans Center for Clinical Research
    New Orleans, Louisiana 70119, United States
  • New Orleans Center for Clinical Research
    New Orleans, Louisiana, United States
  • North Shore Research Associates
    Slidell, Louisiana 70461, United States
  • Sunset Medical Research
    Sunset, Louisiana 70584, United States
  • University of Maryland-Airways Research Center
    Baltimore, Maryland, United States
  • Institute of Asthma and Allergy
    Wheaton, Maryland, United States
  • Pro-Medica Clinical Research Center
    Boston, Massachusetts 02135, United States
  • ClinSite, Inc.
    Ann Arbor, Michigan 48106, United States
  • MedEx HealthCare Research, Inc.
    Saint Louis, Missouri 63108, United States
  • Midwest Chest Consultants, PC
    St. Charles, Missouri 63301-2847, United States
  • C.A.R.E Clinical Research
    St. Louis,, Missouri 63122, United States
  • Office of Keith Popovich, MD
    Butte, Montana, United States
  • Montana Medical Research, LLC
    Missoula, Montana, United States
  • VA Medical Center
    Omaha, Nebraska, United States
  • Advanced Biomedical Research of America
    Las Vegas, Nevada 89119, United States
  • Pulmonary Medicine
    Chapel Hill, North Carolina 27599, United States
  • Charlotte Lung and Health Center
    Charlotte, North Carolina 28207, United States
  • Carolina Pharmaceutical Research, Inc.
    Statesville, North Carolina 28625, United States
  • New Hanover Medical Research
    Wilmington, North Carolina 28412, United States
  • New Horizons Clinical Research, Inc.
    Cincinnati, Ohio 45241, United States
  • COR Clinical Research LLC
    Oklahoma City, Oklahoma 73103, United States
  • Allergy Associates Research Center
    Portland, Oregon 97213, United States
  • Northeast Clinical Research Centers, Inc.
    Allentown, Pennsylvania 18104, United States
  • Keystone Clinical Solutions
    Altoona, Pennsylvania 16602, United States
  • Philadelphia Health Associates - Adult Medicine
    Philadelphia, Pennsylvania 19146, United States
  • Consortium Clinical Research, Ltd.
    Ridley Park, Pennsylvania 19078, United States
  • Safe Harbor Clinical Research
    East Providence, Rhode Island 02914, United States
  • Spartanburg Pharmaceutical Research
    Spartanburg, South Carolina 29307, United States
  • Volunteer Research Group
    Knoxville, Tennessee 37920, United States
  • Breath of Life Research Institute
    Houston, Texas 77084, United States
  • Central Texas Health Research
    New Braunfels, Texas 78130, United States
  • Sylvana Research Associates
    San Antonio, Texas 78229, United States
  • Pulmonary Associates of Fredericksburg, Inc.
    Fredericksburg, Virginia 22401, United States
  • Pulmonary Associates of Richmond, Inc.
    Richmond, Virginia 23225, United States
  • Bellingham Asthma, Allergy & Immunology Clinic
    Bellingham, Washington 98225, United States
  • University of Wisconsin-Medical School
    Madison, Wisconsin 53792, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2002, a primary completion of Mar 2004 and a completion of Mar 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2003
First posted
Jul 9, 2003
Start
Apr 2002
Primary completionActual
Mar 2004
CompletionActual
Mar 2004
Last update
Feb 22, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00064402
Responsible party
Sponsor
First posted
Jul 9, 2003
Start date
Apr 2002
Primary completion
Mar 2004
Completion
Mar 2004
Last update
Feb 22, 2012

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arformoterol tartrate

Start the discussion